Skip to content
  • Home
  • Signal News
  • Biopharma Digest
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact

Pharminent

 Posted in M&A / Deals

Tortugas takes neuro deep dive with $106M to develop Eisai, Hansoh programs

 April 21, 2026

BioSpace

With programs from Eisai and Hansoh Pharmaceutical in hand, Tortugas Neuroscience has emerged with hopes of delivering daily oral treatments to patients with central nervous system conditions.

M&A / DealsNeuroscienceRead full story

Post navigation

Merck, Eisai’s Keytruda triplet fails to improve survival in kidney cancer →
← BioAge says early data suggest ‘best-in-class’ potential for inflammation drug

Categories

© 2026 Pharminent. All rights reserved.

Design by ThemesDNA.com